CA Patent

CA2663116A1 — Inhibitors of bruton's tyrosine kinase

Assigned to Pharmacyclics LLC · Expires 2008-04-03 · 18y expired

What this patent protects

Disclosed herein are compounds that form covalent bonds with Bruton's tyr osine kinase (Btk). Also described are irreversible inhibitors of Btk. Metho ds for the preparation of the compounds are disclosed. Also disclosed are ph armaceutical compositions that include the compounds…

USPTO Abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyr osine kinase (Btk). Also described are irreversible inhibitors of Btk. Metho ds for the preparation of the compounds are disclosed. Also disclosed are ph armaceutical compositions that include the compounds. Methods of using the B tk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseas es or conditions.

Drugs covered by this patent

Patent Metadata

Patent number
CA2663116A1
Jurisdiction
CA
Classification
—
Expires
2008-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.